CHRONIC KIDNEY DISEASE DRUGS MARKET ANALYSIS

Chronic kidney disease includes conditions that damage kidneys and decrease their ability to keep you healthy by filtering wastes from blood. The symptoms of chronic kidney disease includes:

• Have Trouble Concentrating
• Poor Appetite
• Swollen Feet And Ankles
• Dry and itchy skin
• Need to urinate more often, especially at night and others

Chronic kidney can be treated using drug class such as: ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers and others.

Global chronic kidney disease drugs market is estimated to be valued at US$ 13, 220.0 million in 2022 and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030).

Figure 1. Global Chronic Kidney Disease Drugs Market Share (%), by Drug Class, 2022

To learn more about this report, request a free sample copy

Global Chronic Kidney Disease Drugs Market- Drivers

Increasing number of drug approvals by regulatory bodies is expected to drive the global chronic kidney disease drugs market growth over the forecast period.

Increasing number of drug approvals by regulatory bodies is expected to boost the growth of global chronic kidney disease drugs market. For instance, On June 30, 2022, Bayer AG, a pharmaceutical company, announced that the Chinese National Medical Products Administration (NMPA) had granted marketing authorization for Finerenone under the brand name Kerendia. Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is indicated for the treatment of chronic kidney disease (CKD).

Furthermore, In August 2021, AstraZeneca plc., a biopharmaceutical company, announced that Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). 

Figure 2. Global Chronic Kidney Disease Drugs Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Global Chronic Kidney Disease Drugs Market- Driver

Ongoing research and development of novel treatment for chronic kidney disease is expected to drive the global chronic kidney disease drugs market growth.

Manufacturers operating in the global chronic kidney disease drugs market are focusing on the development of novel treatments for chronic kidney disease. For instance, in September 2018, Reata Pharmaceuticals, Inc., a pharmaceutical company, announced positive results from type 1 diabetic chronic kidney disease (T1D CKD) and IgA nephropathy cohorts of a Phase 2 study, PHOENIX, evaluating bardoxolone methyl (bardoxolone) in patients with rare forms of chronic kidney disease (CKD).

Moreover, in September 2019, Ardelyx, Inc. announced positive results from its phase 3 study, AMPLIFY, for tenapanor in combination with phosphate binders for patients with chronic kidney disease (CKD) on dialysis whose hyperphosphatemia was not previously controlled with binders alone.

Thus, the increasing focus of manufacturers on the development of novel products for the treatment of chronic kidney disease is posing a robust growth opportunity for the global chronic kidney disease drugs market

Global Chronic Kidney Disease Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments.

According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies globally. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.

The appendix of the guidelines also provide answers to some general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.

Furthermore, healthcare facilities and researchers are adhering to the following safety measures for ongoing clinical trials:

The healthcare providers obtain consent from patients over the phone or through video conferences. According to a survey conducted by Medidata Solutions, Inc., on April 23, 2020, 45% respondents opted for virtual/telemedicine for consultancy.

The patients receive a phone call for screening of COVID-19 symptoms before the scheduled in-person visits. However, market players and research institutes are focusing on initiating clinical trials associated with COVID-19 in order to understand the effects of chronic kidney disease treatment drugs on patients suffering with COVID-19.

For instance, on July 28, 2020, Reata Pharmaceuticals, Inc. announced that researchers at the New York University (NYU) Grossman School of Medicine will be are initiating an Investigator-Sponsored Trial (IST), BARCONA, to study the effect of bardoxolone methyl (bardoxolone) in patients suffering from COVID-19 and Reata Pharmaceuticals, Inc., is providing the drug supply for the trial.

Global Chronic Kidney Disease Drugs Market: Key Developments

In July 2022, Grupo Olmos, a provider of renal care solutions, announced that the company had acquired renal care business of Diaverum, a renal healthcare provider, which operates in Argentina. The acquisition of renal business will strengthen the renal product portfolio of the company.

In March 2019, Aster Hospitals, the largest private healthcare service providers operating in multiple GCC states, announced that it had launched an awareness and screening initiative to promote the prevention of chronic kidney disease (CKD) through education, awareness, and early diagnosis.

Global Chronic Kidney Disease Drugs Market: Restraint

Lack of awareness of chronic kidney disease is expected to hinder the growth of global chronic kidney disease drugs market. An earlier diagnosis of chronic kidney disease (CKD) could slow the disease progression, prevent complications, and reduce cardiovascular-related outcomes. Early referral to a nephrologist has also been shown to improve outcomes for those who progress to end-stage renal disease. In March 2018, a cross-sectional study was published in BMC Public Health, according to which people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew that medications can help slow the worsening of CKD.  Furthermore, only 23.4% of participants knew that herbal supplements are ineffective in treating CKD.

Key Players

Major players operating in the global chronic kidney disease drugs market include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.